247 related articles for article (PubMed ID: 27812545)
1. Low-dose IL-2 selectively activates subsets of CD4
Hirakawa M; Matos TR; Liu H; Koreth J; Kim HT; Paul NE; Murase K; Whangbo J; Alho AC; Nikiforow S; Cutler C; Ho VT; Armand P; Alyea EP; Antin JH; Blazar BR; Lacerda JF; Soiffer RJ; Ritz J
JCI Insight; 2016 Nov; 1(18):e89278. PubMed ID: 27812545
[TBL] [Abstract][Full Text] [Related]
2. Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease.
Whangbo JS; Kim HT; Nikiforow S; Koreth J; Alho AC; Falahee B; Kim S; Dusenbury K; Fields MJ; Reynolds CG; Alyea EP; Armand P; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Ritz J
Blood Adv; 2019 Apr; 3(7):984-994. PubMed ID: 30936059
[TBL] [Abstract][Full Text] [Related]
3. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.
Matsuoka K; Koreth J; Kim HT; Bascug G; McDonough S; Kawano Y; Murase K; Cutler C; Ho VT; Alyea EP; Armand P; Blazar BR; Antin JH; Soiffer RJ; Ritz J
Sci Transl Med; 2013 Apr; 5(179):179ra43. PubMed ID: 23552371
[TBL] [Abstract][Full Text] [Related]
4. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.
Martin JF; Perry JS; Jakhete NR; Wang X; Bielekova B
J Immunol; 2010 Jul; 185(2):1311-20. PubMed ID: 20543101
[TBL] [Abstract][Full Text] [Related]
5. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD.
Alho AC; Kim HT; Chammas MJ; Reynolds CG; Matos TR; Forcade E; Whangbo J; Nikiforow S; Cutler CS; Koreth J; Ho VT; Armand P; Antin JH; Alyea EP; Lacerda JF; Soiffer RJ; Ritz J
Blood; 2016 Feb; 127(5):646-57. PubMed ID: 26670634
[TBL] [Abstract][Full Text] [Related]
6. CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study.
Jaiswal SR; Zaman S; Nedunchezhian M; Chakrabarti A; Bhakuni P; Ahmed M; Sharma K; Rawat S; O'donnell P; Chakrabarti S
Cytotherapy; 2017 Apr; 19(4):531-542. PubMed ID: 28131632
[TBL] [Abstract][Full Text] [Related]
7. Increased Foxp3
Chen YB; Efebera YA; Johnston L; Ball ED; Avigan D; Lekakis LJ; Bachier CR; Martin P; Duramad O; Ishii Y; Han S; Jung YJ; Lee D; Kunkel L; Negrin RS; Bui JD
Biol Blood Marrow Transplant; 2017 Apr; 23(4):625-634. PubMed ID: 28104514
[TBL] [Abstract][Full Text] [Related]
8. Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation.
Meguri Y; Asano T; Yoshioka T; Iwamoto M; Ikegawa S; Sugiura H; Kishi Y; Nakamura M; Sando Y; Kondo T; Sumii Y; Maeda Y; Matsuoka KI
Front Immunol; 2022; 13():891925. PubMed ID: 35983059
[TBL] [Abstract][Full Text] [Related]
9. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.
Asano T; Meguri Y; Yoshioka T; Kishi Y; Iwamoto M; Nakamura M; Sando Y; Yagita H; Koreth J; Kim HT; Alyea EP; Armand P; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Maeda Y; Tanimoto M; Ritz J; Matsuoka KI
Blood; 2017 Apr; 129(15):2186-2197. PubMed ID: 28151427
[TBL] [Abstract][Full Text] [Related]
10. CD56
Kariminia A; Ivison S; Ng B; Rozmus J; Sung S; Varshney A; Aljurf M; Lachance S; Walker I; Toze C; Lipton J; Lee SJ; Szer J; Doocey R; Lewis I; Smith C; Chaudhri N; Levings MK; Broady R; Devins G; Szwajcer D; Foley R; Mostafavi S; Pavletic S; Wall DA; Couban S; Panzarella T; Schultz KR
Haematologica; 2017 Nov; 102(11):1936-1946. PubMed ID: 28935847
[TBL] [Abstract][Full Text] [Related]
11. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer.
Shah MH; Freud AG; Benson DM; Ferkitich AK; Dezube BJ; Bernstein ZP; Caligiuri MA
Clin Cancer Res; 2006 Jul; 12(13):3993-6. PubMed ID: 16818697
[TBL] [Abstract][Full Text] [Related]
13. IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation.
Sim GC; Liu C; Wang E; Liu H; Creasy C; Dai Z; Overwijk WW; Roszik J; Marincola F; Hwu P; Grimm E; Radvanyi L
Cancer Immunol Res; 2016 Nov; 4(11):983-994. PubMed ID: 27697858
[TBL] [Abstract][Full Text] [Related]
14. Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers.
Ito S; Bollard CM; Carlsten M; Melenhorst JJ; Biancotto A; Wang E; Chen J; Kotliarov Y; Cheung F; Xie Z; Marincola F; Tanimoto K; Battiwalla M; Olnes MJ; Perl S; Schum P; Hughes TE; Keyvanfar K; Hensel N; Muranski P; Young NS; Barrett AJ
Mol Ther; 2014 Jul; 22(7):1388-1395. PubMed ID: 24686272
[TBL] [Abstract][Full Text] [Related]
15. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
[TBL] [Abstract][Full Text] [Related]
16. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.
Carson WE; Fehniger TA; Caligiuri MA
Eur J Immunol; 1997 Feb; 27(2):354-60. PubMed ID: 9045904
[TBL] [Abstract][Full Text] [Related]
17. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
18. Low-dose IL-2 induces CD56
McQuaid SL; Loughran ST; Power PA; Maguire P; Szczygiel A; Johnson PA
Clin Exp Immunol; 2020 Jun; 200(3):228-241. PubMed ID: 31989589
[TBL] [Abstract][Full Text] [Related]
19. Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes.
Haller MJ; Gitelman SE; Gottlieb PA; Michels AW; Perry DJ; Schultz AR; Hulme MA; Shuster JJ; Zou B; Wasserfall CH; Posgai AL; Mathews CE; Brusko TM; Atkinson MA; Schatz DA
Diabetes; 2016 Dec; 65(12):3765-3775. PubMed ID: 27669730
[TBL] [Abstract][Full Text] [Related]
20. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
Xun CQ; Thompson JS; Jennings CD; Brown SA
Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
